These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 17645716

  • 1. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R.
    Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
    [Abstract] [Full Text] [Related]

  • 2. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 3. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
    Carvalho C, Coentrão L, Bustorff M, Patrício E, Sampaio S, Santos J, Oliveira G, Pestana M.
    Clin Transplant; 2011; 25(4):E401-5. PubMed ID: 21457330
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis.
    Baur B, Oroszlan M, Hess O, Carrel T, Mohacsi P.
    Transplant Proc; 2011 Jun; 43(5):1853-61. PubMed ID: 21693289
    [Abstract] [Full Text] [Related]

  • 5. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 6. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 7. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
    McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS.
    Liver Transpl; 2001 Aug 27; 7(8):701-8. PubMed ID: 11510015
    [Abstract] [Full Text] [Related]

  • 8. Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study.
    Fuchs U, Zittermann A, Hakim-Meibodi K, Börgermann J, Schulz U, Gummert JF.
    Transplant Proc; 2011 Jun 27; 43(5):1839-46. PubMed ID: 21693287
    [Abstract] [Full Text] [Related]

  • 9. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM.
    Transplantation; 2010 Jul 15; 90(1):31-7. PubMed ID: 20517177
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 15; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 11. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients.
    van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L.
    Transplantation; 2003 Jun 27; 75(12):1934-9. PubMed ID: 12829890
    [Abstract] [Full Text] [Related]

  • 12. Dyslipidemia during sirolimus therapy in patients after liver transplantation.
    Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg Kh.
    Clin Transplant; 2004 Dec 27; 18(6):642-6. PubMed ID: 15516237
    [Abstract] [Full Text] [Related]

  • 13. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J, del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernández AM, Brunet M.
    Transplantation; 2010 Apr 27; 89(8):994-1000. PubMed ID: 20335831
    [Abstract] [Full Text] [Related]

  • 14. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 27; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 15. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 16. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 20; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 17. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results.
    Masetti M, Rompianesi G, Montalti R, Romano A, Spaggiari M, Ballarin R, Guerrini GP, Gerunda GE.
    Transplant Proc; 2008 Mar 20; 40(6):1947-9. PubMed ID: 18675097
    [Abstract] [Full Text] [Related]

  • 18. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
    Transpl Immunol; 2006 Jun 20; 16(1):46-51. PubMed ID: 16701176
    [Abstract] [Full Text] [Related]

  • 19. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation.
    Moro JA, Almenar L, Martínez-Dolz L, Sánchez-Lázaro I, Agüero J, Salvador A.
    Transplant Proc; 2008 Nov 20; 40(9):3034-6. PubMed ID: 19010183
    [Abstract] [Full Text] [Related]

  • 20. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.